Sa'ar Yaniv

Stock Analyst at Roth Capital

(1.60)
# 3,045
Out of 4,829 analysts
3
Total ratings
33.33%
Success rate
4.06%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Sa'ar Yaniv

Galectin Therapeutics
Oct 19, 2017
Initiates: Buy
Price Target: $8
Current: $1.40
Upside: +471.43%